The future of neuroimaging analysis is here and Qynapse is leading the way. For clinicians on the front lines, for patients and their families, for payers, and for pharma – we offer peace of mind by providing results you can trust.
Combining MRI scans and artificial intelligence to produce rapid, actionable insights into central nervous system (CNS) disorders.
On the front lines of neuroscience, imaging for diagnosis and prognosis of central nervous system (CNS) diseases like Alzheimer’s, Multiple Sclerosis and Parkinson’s has reached new heights. However, in too many cases, neuroimaging leaves more questions than answers.
When health practitioners, patients and caregivers have a more accurate and reliable diagnosis of CNS disease, timely interventions and lifestyle changes are more successful and patient outcomes can dramatically improve. And when pharmaceutical companies have a higher probability of success in clinical trials, their potentially life-changing therapies can make an impact sooner.
The Qynapse neuroscience team, with the support and guidance of CNS disease experts around the world, is wholly dedicated to aspiring to build tools and software that analyze brain images and other markers of neurodegeneration to create the clearest, most accurate and reliable predictors and objective measures of CNS disorders.
On the front lines of neuroscience, imaging for diagnosis and prognosis of central nervous system (CNS) diseases like Alzheimer’s, Multiple Sclerosis and Parkinson’s has reached new heights. However, in too many cases, neuroimaging leaves more questions than answers.
When health practitioners, patients and caregivers have a more accurate and reliable diagnosis of CNS disease, timely interventions and lifestyle changes are more successful and patient outcomes can dramatically improve. And when pharmaceutical companies have a higher probability of success in clinical trials, their potentially life-changing therapies can make an impact sooner.
The Qynapse neuroscience team, with the support and guidance of CNS disease experts around the world, is wholly dedicated to aspiring to build tools
and software that analyze brain images and other markers of neurodegeneration to create the clearest, most accurate and reliable predictors and objective measures of CNS disorders.
%
Misdiagnosis Rate
The current rate of misdiagnosis in CNS disease ranges up to 30%.
Automated Measures
Of neuroinflammation and neurodegeneration
Normative Dataset
Largest normative dataset of over 10,000 brain scan images
Advanced Technology
20 algorithms
How we get there.
QyScore® also has demonstrated superior performance compared to certain other automated state-of-the-art methods and has been validated against gold-standard manual segmentation.
AI-powered and proprietary neuroimaging software platform, QyScore®, aims to provide physicians, pharma researchers and payers an objective layer of precision when making a CNS disease diagnosis. QyPredict®, for research use only, is being designed to transform what we know about CNS disease
trajectory by combining genomics, biofluids, neuroimaging, cognitive endpoints and measures of activities of daily living to help guide health decisions.
Marwan N. Sabbagh
MD, FAAN, CCRI
Going from a diagnostic accuracy of 66-70% to better than 90% is today the most pressing topic for the Alzheimer’s disease community. I am glad to see innovative organizations like Qynapse leading the way and contributing to transform the diagnosis of Alzheimer’s disease.
David Merrill, MD, PhD
Director | Pacific Brain Health Center Pacific Neuroscience Institute
I’m excited to use QyScore® to quantify both volumetric and white matter integrity in our patients – bringing such an important layer of precision and objectivity to inform our clinical decisions.
Olivier Courrèges
Founder & CEO | Qynapse
When someone you love is declining mentally, there's nothing worse than not having a clear diagnosis as to why. That's why Qynapse is on a mission to transform time to diagnosis and the accuracy for diagnosis for CNS disease.
Srinivas Peddi, MD
Radiologist & Board Member | Tower Imaging Medical Group
When you remove air from a ball, it’s hard to figure that out until it’s lost a lot of volume. But if we had a tool that would let us measure more precisely? That’s super helpful. And that's what Qynapse provides.
Diane Souza
Former CEO | UnitedHealthcare Specialty Benefits
Payers have developed very sophisticated systems and data sets to help their members, healthcare providers and teams make better decisions about healthcare. What Qynapse provides further enhances that decision making, resulting from the whole being greater than the sum of the parts.
Bruno Dubois, MD, PhD
Professor of Neurology | Sorbonne University, Director of the Institute of Memory and Alzheimer’s Disease (IM2A) | Pitié Salpêtrière Hospital in Paris
In light of the recent breakthrough for Alzheimer’s patients – the approval of new treatment options by the FDA, Qynapse’s vision is becoming even more critical to advance the early detection of Alzheimer’s disease and to precisely monitor the therapy efficacy and safety.
Qyscore® is a medical device software FDA-cleared – class II and CE-marked (class IIa).
Indications for Use in the U.S. (FDA): QyScore® is intended for automatic labeling, visualization and volumetric quantification of segmentable brain structures and lesions from a set of MR images. Volumetric data may be compared to reference percentile data. QyScore® is not intended for use in clinical scenarios that require evaluation of the number of the white matter hyperintensities.
Indications for Use in Europe (CE): QyScore® is an advanced processing and visualization software for automatic labeling and volumetric quantification of segmented central nervous system structures for patients older than 18 years of age. The software is intended to be used by medical personnel or neuroimaging trained personnel to support diagnosis of central nervous system diseases.